Peak Bio (NASDAQ:PKBO) Stock Price Down 20.5%

Peak Bio, Inc. (NASDAQ:PKBOGet Rating) was down 20.5% during trading on Wednesday . The stock traded as low as $1.01 and last traded at $1.71. Approximately 268,273 shares changed hands during mid-day trading, an increase of 303% from the average daily volume of 66,582 shares. The stock had previously closed at $2.15.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH started coverage on shares of Peak Bio in a report on Friday, November 4th. They issued a “buy” rating and a $15.00 price objective for the company.

Peak Bio Stock Performance

The stock’s 50 day moving average price is $4.97.

Peak Bio Company Profile

(Get Rating)

Peak Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. Its lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome.

See Also

Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with's FREE daily email newsletter.